<DOC>
	<DOCNO>NCT00654030</DOCNO>
	<brief_summary>Rationale : Vaccines make allogeneic tumor cell may help body build effective immune response kill tumor cell . The Purpose study evaluate effect lung cancer vaccine patient Stage I Stage II Non-Small Cell Lung Cancer ( NSCLC ) completion initial definitive therapy .</brief_summary>
	<brief_title>Allogeneic Cellular Vaccine 1650-G Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>The study open label investigation cellular vaccine call 1650-G . Patients receive 2 vaccine injection intradermally thigh give 4 week apart . Patients follow weekly vaccine injection monthly 4 month . Patient follow-up continue evaluation 6 month 1 year receive first vaccine injection . Immunologic response vaccine assess blood sample obtain visit follow immunization .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically confirm Stage I Stage II NonSmall Cell Lung Cancer Surgically resect least 4 week ago 6 month ago Bronchoalveolar carcinoma allow Completion chemotherapy radiation give conjunction Surgery ( neoadjuvant adjuvant ) No evidence disease follow initial therapy evidence CXR , CT PET scan within 6 week enrollment ECOG performance status 0 2 Adequate organ marrow function define follow : Hemoglobin â‰¥9.0 gm/dL Bilirubin &lt; 2.5 x upper limit normal AST &lt; 2.5 x upper limit normal ALT &lt; 2.5 x upper limit normal Creatinine &lt; 3 mg/dL Women childbearing potential must negative pregnancy test willing use acceptable method contraception week 16 . Cardiovascular disease define : New York Heart Association Class III IV ( Section 19.2 ) congestive heart failure hemodynamically significant valvular heart disease myocardial infarction within last six month active angina pectoris uncontrolled ventricular arrhythmia stroke within one year know cerebrovascular disease History HIV , infectious hepatitis , chronic immunosuppressive disease concurrent shorter course immunosuppressive medication 16 week study treatment History allergic reaction colony stimulate factor ( GCSF , GMCSF ) Female patient must pregnant breastfeeding . History participation investigational drug study within 4 week precede initiation study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Lung Cancer Vaccine</keyword>
	<keyword>Early Stage Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>